In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $2.84.
According to TipRanks, Matteis is a 4-star analyst with an average return of 6.7% and a 46.91% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neurogene, ACADIA Pharmaceuticals, and Alnylam Pharma.
Currently, the analyst consensus on Vigil Neuroscience Inc is a Moderate Buy with an average price target of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $12.78 and a one-year low of $2.53. Currently, Vigil Neuroscience Inc has an average volume of 140.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vigil Neuroscience Inc (VIGL) Company Description:
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Read More on VIGL:
- Acrivon Therapeutics appoints Magovcevic to board of directors
- Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
- Vigil Neuroscience extends projected cash runway into second half of 2025
- Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- Vigil Neuroscience downgraded to Underweight from Equal Weight at Morgan Stanley
